DALLAS, Jan. 13, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech and drug company Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/SPPI
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Spectrum Pharmaceuticals Inc. (SPPI) is a commercial stage biopharmaceutical company, engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. The Company's product is apaziquone (formerly EOquin), which is in two phase 3 clinical trials for non-muscle invasive bladder cancer under a collaboration with Allergan Inc. Another drug, ozarelix, is in a phase 2 clinical trial for benign prostatic hypertrophy (BPH).
Message Board Search for SPPI: http://www.boardcentral.com/boards/SPPI
In the report, the analyst notes:
"For the three-month period ended September 30, 2009, SPPI recorded a net loss of approximately $8.4 million, compared to a net loss of approximately $8.8 million for the three-month period ended September 30, 2008.
"SPPI recently announced that the second of two phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to SPPI. The apaziquone registration plan, which the U.S. Food and Drug Administration (FDA) concurred with under a Special Protocol Assessment, calls for two double blind, placebo-controlled, randomized phase 3 clinical studies, each with 562 evaluable patients with Ta G1 or G2 low risk non-invasive bladder cancer."
To read the entire report visit: http://www.beaconequity.com/i/SPPI
See what investors are saying about SPPI at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.